BIOBIJOU Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	33,706	29,633	17,130
Revenue Growth (YoY)	96.77%	72.99%	-
Cost of Revenue	14,645	14,815	8,871
Gross Profit	19,062	14,819	8,259
Selling, General & Admin	7,685	3,982	2,311
Research & Development	748.94	1,213	632.7
Amortization of Goodwill & Intangibles	24.63	13.84	6.53
Other Operating Expenses	64.03	47.52	29.74
Operating Expenses	8,925	5,592	3,094
Operating Income	10,137	9,227	5,165
Interest Expense	-91.75	-444.24	-594.63
Interest & Investment Income	373.28	205.4	126.48
Currency Exchange Gain (Loss)	690.11	765.23	400.31
Other Non Operating Income (Expenses)	8.87	-922.33	-949.25
EBT Excluding Unusual Items	11,117	8,831	4,148
Gain (Loss) on Sale of Investments	118.45	148.3	79.14
Gain (Loss) on Sale of Assets	-	-	0.65
Pretax Income	11,236	8,979	4,227
Income Tax Expense	2,359	1,791	917.41
Net Income	8,876	7,188	3,310
Net Income to Common	8,876	7,188	3,310
Net Income Growth	168.17%	117.16%	-
Shares Outstanding (Basic)	13	11	11
Shares Outstanding (Diluted)	13	11	11
Shares Change (YoY)	22.46%	6.20%	-
EPS (Basic)	674.76	630.08	308.13
EPS (Diluted)	674.76	630.08	308.13
EPS Growth	118.98%	104.48%	-
Free Cash Flow	2,707	461.05	4,038
Free Cash Flow Per Share	205.77	40.41	375.87
Gross Margin	56.55%	50.01%	48.21%
Operating Margin	30.07%	31.14%	30.15%
Profit Margin	26.33%	24.26%	19.32%
Free Cash Flow Margin	8.03%	1.56%	23.57%
EBITDA	10,913	9,927	5,752
EBITDA Margin	32.38%	33.50%	33.58%
D&A For EBITDA	775.81	700.16	587.04
EBIT	10,137	9,227	5,165
EBIT Margin	30.07%	31.14%	30.15%
Effective Tax Rate	21.00%	19.95%	21.70%
Advertising Expenses	-	469.22	188.63

Source: S&P Global Market Intelligence. Standard template. Financial Sources.